Posted by Michael Wonder on 09 Sep 2024
Amneal and Shilpa announce US FDA approval of Boruzu, the first ready to use version of bortezomib for subcutaneous administration
5 September 2024 - Ready to use oncology treatment used for multiple myeloma and mantle cell lymphoma.
Amneal Pharmaceuticals and Shilpa Medicare announced US FDA approval of Boruzu, a new presentation of bortezomib for ready to use subcutaneous administration or intravenous administration.
